For research use only
| Cat No. | ABC-TC0591 |
| Product Type | Mouse Lung Cancer Cell Lines |
| Species | Mouse |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Cancer |
| Product Code | LL/2 (LLc1); LL/2; LL2; LLC1; LLC; Lewis lung carcinoma line 1; Lewis lung carcinoma; Lewis Lung Cancer; Lewis-Lung; Lewis Lung |
Lewis Lung Carcinoma 1 (LLC1) cells are murine lung cancer cells with metastatic and epithelial-mesenchymal features for lung cancer studies.
LL/2 (LLc1), also known as Lewis Lung Carcinoma 1, is a murine lung adenocarcinoma cell line originally derived from a spontaneous lung tumor in a C57BL mouse. These epithelial-like cells grow as an adherent monolayer and are widely used in preclinical oncology models due to their high tumorigenicity and metastatic potential, particularly to the lungs. They are hypotetraploid and express both cytokeratin and vimentin, indicating epithelial-mesenchymal characteristics. The cells express genes involved in inflammation, angiogenesis, and immune evasion, including VEGF, MMPs, and PD-L1. They are characterized by their aggressive growth rate and resistance to immune surveillance, making them a robust model for studying immuno-oncology and tumor-host interactions.
| Product Code | LL/2 (LLc1); LL/2; LL2; LLC1; LLC; Lewis lung carcinoma line 1; Lewis lung carcinoma; Lewis Lung Cancer; Lewis-Lung; Lewis Lung |
| Species | Mouse |
| Cat.No | ABC-TC0591 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Growth Mode | Adherent and Suspension |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Lung |
| Disease | Lung Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Mouse Lung Cancer Cell Lines |
LL-2 (LLC1) cells are widely utilized in cancer research for evaluating drug-induced cytotoxicity via focus assays, providing insights into agent-specific effects on cancer cell viability. They are integral to syngeneic animal models for in vivo assessment of anticancer treatment efficacy and safety. Additionally, LL-2 (LLC1) cells facilitate the identification of molecular targets by testing antibodies or inhibitors, supporting the development of targeted therapies. Overall, they are essential tools for investigating drug response, therapeutic outcomes, and cancer biology mechanisms.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $200 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
The LL/2(LLc1) cells exhibit heterogeneous morphology, with both epithelial-like cells and round cells present simultaneously in varying proportions. Cells are loosely attached to the culture vessel. There may be a small number of floating cells; when adherent cells are abundant, the suspension cells can be discarded.
Be careful to control the cell density to avoid it being too high, as long-term high-density culture can lead to cell stacking or clustering.
The LL/2 cells are highly tumorigenic and can form tumors and metastases when implanted into immunocompromised or syngenic C57BL/6 mice. However, they are weakly metastatic in mice and have been described as non-responsive to checkpoint blockade immunotherapy.
